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Abstract 
 
Examination of Believability as a Mediator of a Novel Biological Intervention for Positive 
Psychotic Symptoms on Symptom-Related Distress in Schizophrenia 
Alexander Gehrt Geboy 
James D. Herbert, Ph.D. 
Evan M. Forman, Ph.D. 
Richard C. Josiassen, Ph.D. 
 
 
Believability refers to the degree of conviction in the validity of one’s subjective 
experience as reflections of reality.  Distress refers to troubling affective reactions to one’s 
experience, and is likely exacerbated by increased believability.  Many standard psychological 
treatments targeting psychotic symptoms include verbal challenges, reality testing, and thought 
control techniques, and directly or indirectly involve thought suppression and experiential 
avoidance.  Research has demonstrated, however, that such direct cognitive control strategies 
may increase the frequency of and distress associated with problematic cognitions. Research has 
further suggested that novel behavior therapy programs that effectively reduce believability 
without directly challenging or targeting cognitive content can reduce distress associated with, 
and the functional impact of, positive psychotic symptoms (i.e., hallucinations and 
delusions).  This pilot study, couched within a randomized, double-blind, placebo-controlled, 
two-arm parallel study, examined believability and distress associated with psychotic symptoms 
in a small sample of inpatients (n=6) in the state hospital system.  Participants were assessed at 
baseline/ day 1, mid-treatment, and post-treatment on 4 distinct measures.  Due to the smaller 
than anticipated sample (4 active drug vs. 2 placebo), formal statistical analyses proposed in the 
hypotheses were not attempted.  Findings revealed only modest associations between 
believability and positive psychotic symptoms.  However, due to small sample size, it cannot be 
determined whether this association is statistically or clinically significant.  Distress did not 
appear to be associated with believability among these patients.  Implications and future 
directions are discussed.! 

 1 
Introduction 
1.1 The Treatment of Positive Psychotic Symptoms in Schizophrenia 
 
 Schizophrenia is a chronic, debilitating, mental disorder with a prevalence rate reported 
to be in the range of 0.5% to 1.5% worldwide (American Psychiatric Association., 2000).  Key 
among its essential features are positive psychotic symptoms, including hallucinations and 
delusions. The term “positive” implies an excess or distortion of the individual’s normal 
functioning1.  Hallucinations represent distortions in thought perception occurring in any sensory 
modality (i.e., auditory, visual, olfactory, gustatory, or tactile).  Delusions are erroneous beliefs 
usually involving a misinterpretation of perceptions or experiences, contextually derived from a 
variety of themes (e.g., persecutory, referential, somatic, religious, or grandiose) (American 
Psychiatric Association., 2000).  A core problem in schizophrenia is the persistence of these 
symptoms, which permits them to become crystallized core beliefs and to interfere with the 
individual’s functioning. 
 As these core beliefs are woven into the individual’s perceived reality, attempts to dispute 
them are typically met with significant resistance.  In addition to traditional pharmacological 
treatments, psychosocial programs exist designed to reduce the believability, frequency, and 
intensity of these symptoms through direct challenges to the content of positive psychotic 
symptoms.  Treatment methods often include verbal challenges, reality testing, and focusing and 
distracting techniques (Chadwick & Lowe, 1994; Haddock, Slade, Bentall, Reid, & Faragher, 
1998; Himadi & Kaiser, 1991; Lowe & Chadwick, 1990).  These direct challenges sometimes 
employ suppression and/ or avoidance as methods of regulating content.  However, there is 
persuasive evidence to suggest that directly challenging content with the intention of reducing 
                                                
1 It should be noted that what this thesis implies by “positive” psychotic symptoms” is not the entire 
constellation of florid psychotic symptoms categorized within the positive scale of the Positive and 
Negative Syndrome Scale (PANSS) for schizophrenia (see page 71 below) (Kay, Fiszbein, & Opler, 1987) 
as distinguished from both negative and general psychotic symptoms.  Rather, the phrase “positive 
psychotic symptoms” represents only hallucinations and delusions.  
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believability may lead to a number of negative outcomes, including increased frequency and 
believability of positive symptoms (Bach & Hayes, 2002). 
1.2 Psychopathology and the Theory of Acceptance and Commitment Therapy 
 
 Psychosocial interventions that target the believability of problematic cognitions without 
directly challenging their content have recently been developed.  Some of these interventions 
have emerged out of the cognitive therapy traditions utilizing mindfulness and acceptance 
strategies as ways to defuse from internally generated and distorted cognitions (Herbert & 
Forman, 2011).  Acceptance and commitment therapy (ACT) (Hayes, Strousahl, & Wilson, 1999) 
is one such example. 
 To understand ACT in the context of psychopathology and believability, a description of 
its underlying theory is necessary.  Although complete details are beyond the scope of this work, 
ACT is based on relational frame theory (RFT) (Barnes-Holmes, Barnes-Holmes, McHugh, & 
Hayes, 2002; Hayes, Barnes-Holmes, & Roche, 2001; Hayes et al., 1999) a behaviorally oriented 
theory and research program that applies learning principles to the study of language and 
cognition.  The primary assertion of RFT is that verbally-mediated private events (e.g. cognitions, 
emotions, memories) do not influence behavior directly through their content or frequency, but 
instead through the context in which they occur.  At the core of RFT lies the principle that verbal 
behavior is a specific class of generalized operant that corresponds to the ability to respond to a 
stimulus in relation to another stimulus on the basis of properties defined by society.  Once 
established, these derived stimulus relations (i.e., “relational frames” or learned patterns of 
contextually controlled and arbitrarily applicable relational responding) are difficult to break up, 
even with direct, contradictory training (Wilson & Hayes, 1996).  Once verbal relations are 
derived, they remain; one can add to or elaborate them, but one cannot completely eliminate them 
(Pankey & Hayes, 2003). 
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 According to an RFT account of psychopathology, people with serious psychiatric 
problems can become entangled in the literal content of their own unusual, frightening, and often 
bizarre thoughts – which form the basis for hallucinations and delusions – because contexts that 
encourage such entanglement are common, while those that weaken it are not.  As entanglement 
increases, bizarre thoughts become more elaborate, crystallized, and believable.  Furthermore, the 
transfer of negative emotional functions increases.  Unfortunately, this is likely to lead to 
suppression and avoidance, which only increases the functional salience and often the frequency 
of the avoided thoughts and results in a more elaborate relational network focused on psychotic 
symptoms (Pankey & Hayes, 2003).  Because attempts to directly change verbal relations only 
add new verbal relations elaborating the existing network, a vicious cycle is established.  
Therefore, for people suffering from serious psychiatric problems, positive psychotic symptoms 
tend to become the fulcrum around which life is centered, playing a destructive role in the 
regulation of overt behavior (Pankey & Hayes, 2003). 
 Thus, directly challenging problematic cognitive content may lead to a number of 
negative outcomes.  Specifically, means for achieving unhealthy attempts of control or 
suppression are accomplished through both experiential avoidance (i.e., a pathological process 
whereby one attempts to escape, avoid, or otherwise control private, internally generated events 
[e.g., thoughts and feelings] even when doing so is ineffective and disrupts functioning), and 
cognitive fusion (i.e., an individual’s identification with and belief in his/ her thoughts, to the 
point where they have literally “fused” to reality (Hayes et al., 1999).  From an ACT perspective, 
using such techniques paradoxically increases self-focused attention, which directs attention to 
internally generated stimuli and cognitions at the exclusion and expense of outward focus.  
Potential negative outcomes of self-focused attention promoted by suppression and avoidance 
behaviors are an increase in the frequency of unwanted thoughts (Salkovskis & Campbell, 1994; 
Wegner, Schneider, Carter, & White, 1987), exacerbated intrusive thoughts, psychological 
distress, autonomic arousal, and further auditory hallucinations. 
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 Thus, the goal of ACT is to change one’s relationship to one’s symptoms rather than to 
change the symptom’s frequency, by helping to become less entangled with the symptoms and 
more focused on effective behavior.  To do so, ACT teaches to (1) identify and abandon 
internally oriented control strategies, (2) accepts the presence of difficult thoughts or feelings, (3) 
learn to “just notice” the occurrence of these private experiences, without struggling, 
argumentation, or fusion, and (4) focus outwardly to diminish self-focused attention and promote 
experiential participation.  In using such techniques, ACT has been shown to decrease the 
believability of negative private events in some clinical populations (Zettle & Hayes, 1986) (see 
Hayes et al., 1999 for a review). 
1.3 ACT for Psychosis and the Construct of Believability 
 
 Controlled research on ACT for the treatment of psychotic symptoms, though limited, is 
very promising.  A prominent construct within this body of research is believability.  
Believability will be defined as the degree to which people believe that the content of their 
delusions or hallucinations correspond to reality.  For example, if a person has infrequent (e.g., 
occurring for a few seconds on a weekly basis) auditory hallucinations (e.g., faint voices or other 
obscure noises), believes they are solely internally generated and related to the self, and is neither 
distressed nor convinced by their presence, this person will probably rate them low in 
believability.  However, if auditory hallucinations are firmly held, occur continuously, are 
distressing, persuasive, and are perceived to originate from outside of the head, this person is 
more likely to attribute a high degree of believability to them. 
 The study by Bach and Hayes (2002) was the first to focus on believability in the 
treatment of psychosis.  A total of 80 psychotic inpatients experiencing positive symptoms were 
randomly assigned to receive four session of ACT or treatment as usual (TAU).  Results from this 
research indicated while ACT patients admitted to more psychiatric symptoms (21 ACT patients 
[60%] versus 11 TAU patients [31%] reporting symptoms at follow-up), they were four times 
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more likely to remain out of the hospital, suggesting that symptom reporting in the ACT 
condition likely reflected a sense of acceptance of symptoms.  Furthermore, ACT patients also 
showed reduced believability in the literal reality of the symptoms they experienced.  In fact, no 
ACT patients who both admitted symptoms and showed reduced believability in them were 
rehospitalized.  Finally, believability, as measured through self-report (see Bach and Hayes 
(2002) p.4 for details) decreased from a mean value of 78.7 at baseline to 40.7 at follow-up 
among ACT participants and from a mean value of 75.4 at baseline to 63.6 at follow-up among 
TAU participants.  The difference in believability ratings between these two groups was 
statistically significant F(1, 29)= 4.36, p< 0.05.  This further suggests reduced believability of 
psychotic symptoms played a role in the impact of ACT on rehospitalization.   
 Gaudiano and Herbert (2006) replicated and extended these findings.  Forty inpatients 
with affective and non-affective psychosis were randomly assigned to enhanced treatment as 
usual (ETAU) or treatment as usual (TAU) plus brief (3 sessions on average, varying based on 
length of stay) ACT treatment.  At hospital discharge, ACT produced greater improvements in 
affective symptoms, social impairment, and hallucination-related distress.  Interestingly, these 
results were noted to be consistent with predictions from RFT (Hayes et al., 2001), suggesting 
that subjective distress, which breeds further self-focused attention, would be decreased if one 
could defuse from and therefore believe less in entangled cognitions.   
 Though no formal mediation analyses were run in this study, as noted by the authors, 
believability of hallucinations only decreased post-treatment in the ACT group, and change in this 
domain covaried with change in distress after controlling for change in symptom frequency.  
These findings suggest that hallucination believability and distress are more strongly related over 
time than hallucination frequency and distress, making believability a potentially important target 
of intervention.   
 In a follow up study, Gaudiano, Herbert, and Hayes (2010) addressed the issue of 
mediation with the same data collected in Gaudiano and Herbert (2006).  They hypothesized 
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hallucination believability would statistically mediate the relationship between treatment 
condition and the outcome of hallucination-associated distress.  Their results confirmed this 
hypothesis; hallucination believability appeared to explain the effect of ACT on hallucination-
related distress relative to those receiving TAU alone.   
 Measures of believability of one’s thoughts have been used in other ACT clinical trials 
and have demonstrated successful treatment mediation across a range of comparison conditions.  
In a re-analysis of an earlier study comparing ACT with traditional cognitive therapy for 
depressed outpatients (Zettle & Hayes, 1986), Hayes, Luoma, Bond, Masuda and Lillis (2006) 
reported that the effects of ACT on self-reported and interviewer-related depressive symptoms 
were statistically mediated by the believability of automatic thoughts, but not by their frequency.  
In a more recent trial, Verra, Hayes, Roget, and Fisher (2008) randomly assigned substance abuse 
counselors to receive education alone or an ACT workshop designed to increase willingness to 
face the emotional and cognitive barriers to learning before being exposed to an educational 
program about the use of evidence-based pharmacotherapy for addiction.  Results showed ACT 
participants acknowledged more barriers to using this knowledge (e.g., co-workers would not like 
it), but greater decreases in the believability of these apparent barriers, such that believability 
mediated the effect of treatment condition on increasing evidence-based pharmacotherapy 
referrals at follow-up.  Taken together, these findings suggest that believability may be a common 
pathway or mechanism by which various psychosocial treatments operate.   
1.4 Understanding Mechanisms of Treatment Effects 
 
 The importance of mediation testing is to identify possible mechanisms through which a 
treatment might influence a dependent variable and achieve its effects.  It posits the means by 
which a causal effect may occur.  The identification of a mediator, though, does not directly 
confirm it as a mechanism of change.  Demonstrating causality is complex, and whereas all 
mechanisms are mediators, not all mediators are causal mechanisms.  After mediation is 
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established, further research must be conducted to demonstrate definitive causality (Kraemer, 
Wilson, Fairburn, & Agras, 2002).  Once identified, mechanisms of change can inform future 
studies, facilitate the development of innovative treatments, and identify ineffective and 
redundant therapeutic elements (Kraemer et al., 2002).   
 With this said, the rationale for using mediation analysis in this study was to investigate 
whether a psychosocial variable can act as a mediator in a biological treatment study.  Combining 
procedurally different treatments (i.e., psychosocial and pharmacological) is becoming 
commonplace in the treatment of psychiatric disorders (Kraemer et al., 2002).  The rationale for 
examining treatment mechanisms for such hybrid treatments is that if treatments are combined 
successfully, knowing what the different mechanisms of change are will not only allow for a 
more dynamic approach to treating disorders, but will clue researchers into contrasting and 
incompatible mechanisms (Kraemer et al., 2002).  Rarely, though, have studies crossed levels of 
analysis (i.e., studying psychosocial variables as mechanisms of biological treatment effect, or 
vice versa) within one treatment study.  One benefit of this approach, following the logic put forth 
by Kreamer et al. (2002), is that any variable (e.g., believability) could be revealed as a critical 
core variable potentially mediating multiple effective treatments.  In this way, identifying 
mediators may advance the etiological understanding of clinical disorders as well as their 
treatment.   
1.5 Believability as a Mechanism of Change 
 
 It is in this context, along with the findings of the research cited above, that we made the 
argument for believability as a mediator and potential mechanism of change in psychosocial 
treatment research.  Although studies of different patient populations have identified similar 
mediation effects (Gaudiano, Herbert, & Hayes, 2010; Hayes, Luoma, Bond, Masuda, & Lillis, 
2006; Zettle & Hayes, 1986), no previous clinical trial of a biological treatment has examined 
psychological mediators of treatment effects on psychotic symptom outcomes.  Furthermore, 
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while the research of Gaudiano et al. (2010) along with the treatment study of Bach and Hayes 
(2002) point to believability as an important factor in acceptance-based behavior therapy for 
psychosis, it is not known whether believability is only operative for psychological treatments 
like ACT (which directly target it), or if it is a common pathway through which multiple 
interventions might also operate. 
Again, crossing levels of analysis, in this case positing the psychosocial variable of 
believability as a mediator of a novel biological intervention, has not been previously attempted, 
to our knowledge.  Therefore, it is a unique aspect of this study that whereas the construct of 
believability was hypothesized as a mediator between a novel biological intervention and positive 
psychotic symptom related distress, no psychosocial treatment was implemented.  The ultimate 
aim of this line of research is not only to determine whether believability stands as a key 
treatment mechanism – even in a biologic intervention for psychosis – but also whether 
believability can act as a critical core variable to mediate many (perhaps even all) effective 
treatments for psychosis, regardless of their type.  The following section outlines the larger 
treatment study through which this project was made possible.  
1.6 Tolvaptan for Hyponatremia in Patients with Psychiatric Disorders 
 
 Hyponatremia is a common electrolyte disorder, with prevalence rates of 1-2.5% in 
general hospital populations (Adrogué & Madias, 2000; Josiassen et al., 2010).  It is defined as a 
decrease in serum sodium concentration to a level below 136 millimoles per liter (Adrogué & 
Madias, 2000).  It represents an excess of water in relation to existing sodium within extracellular 
fluid – an indication of a disturbance in water regulation either by excessive fluid intake or 
exaggerated renal water retention.  While many aspects of hyponatremia are incompletely 
understood, with numerous potential etiologies, it nearly always implies inappropriate secretion 
of the pituitary hormone arginine vasopressin (AVP; anti-diuretic hormone ADH) (Josiassen et 
al., 2010).   
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The U.S. Food and Drug Administration (FDA) recently approved SAMSCA™ 
(tolvaptan) as an oral selective vasopressin antagonist for the treatment of patients with clinically 
significant hyponatremia, including patients with heart failure, cirrhosis, and the syndrome of 
inappropriate anti-diuretic hormone (SIADH).  Though tolvaptan has been shown to normalize 
serum sodium concentrations, it has not been established that raising serum sodium with 
tolvaptan provides any symptomatic benefit to patients. 
 Though symptomatic benefit has not yet been established, this pharmacologic advance 
has important implications for the treatment of hyponatremia in schizophrenia (Adrogué & 
Madias, 2000; Josiassen et al., 2008).  Causes of hyponatremia in this population are difficult to 
detect, as there is little reliable information available about clinical and demographic risk factors.  
Most information comes from case reports or case series of patient studies after the development 
of severe symptoms.  Many cases are no doubt due to well-known conditions, either medical or 
iatrogenic in nature (Josiassen et al., 2010).  SIADH is often proposed as a casual factor, and 
there is evidence of excessive release of agrininge vasopressin (AVP) in this population (Delva, 
Crammer, & Lawson, 1990; Goldman, Luchins, & Robertson, 1988).  Other factors include 
increases in water consumption from psychiatric conditions (delusional states, obsessive-
compulsive behavior) and dry mouth associated with the anticholinergic properties of various 
psychotropic drugs.  Polydipsia is often associated with hyponatremia, suggesting that some 
unspecified renal dysfunction is a contributing factor.  There are care reports suggesting that risk 
for hyponatremia is increased by treatment with tricyclic antidepressants, selective serotonin 
reuptake inhibitors (SSRIs), opiate derivates, mood stabilizers or calcium channel blockers 
(Adrogue, 2005; Siegler, Tamres, Berlin, Allen-Taylor, & Strom, 1995).  Other factors include 
age, the use of diuretics, fluoxetine, and important co-morbid conditions including elevated 
creatinine levels, chronic obstructive pulmonary disease, hypertension, systolic blood pressure 
and diabetes (Bremmer & Reagan, 1991). 
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It has been established that severe hyponatremia in schizophrenia is associated with 
increased mortality, morbidity, and longer hospital stays (Siegler et al., 1995; Verghese, de Leon, 
& Josiassen, 1996; Vieweg et al., 1985).  In addition, hyponatremia in schizophrenic patients is 
often accompanied by increased symptoms of intense fear, agitation, severe anxiety, and 
intensified psychotic symptoms (Cosgray, Hanna, Davidhizar, & Smith, 1990; Riggs, Dysken, 
Kim, & Opsahl, 1991).  Additionally, a limited but growing literature suggests that abnormalities 
in this population associated with hyponatremia extend into cognitive and motor realms (Emsley, 
Spangenberg, Roberts, Taljaard, & Chalton, 1993; Schnur, Wirkowski, Reddy, Decina, & 
Mukherjee, 1993; Shutty, Briscoe, Sautter, & Leadbetter, 1993; Torres, Keedy, Marlow-
O'Connor, Beenken, & Goldman, 2009). 
 Since 2003, Dr. Richard Josiassen has been studying the efficacy of various selective 
vasopressin antagonists for the treatment of hyponatreamia in schizophrenic patients.  None of the 
above studies, however, focused on cognitive and/ or behavioral abnormalities in schizophrenia.  
The introduction of cognition into this research first occurred in the form of limited pilot data 
collected as part of the pivotal Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT) 
(Schrier et al., 2006).  At Dr. Josiassen’s Norristown State Hospital site, cognitive functioning 
was assessed (n=9) at baseline and at Day 30 using the Brief Assessment of Cognition in 
Schizophrenia (BACS).  The BACS assess verbal memory and learning, working memory, motor 
speed, attention, executive functioning, and verbal fluency.  Despite a very small and unbalanced 
sample (tolvaptan = 3; placebo = 6), tolvaptan was associated with an increase in BACS 
composite scores that approached conventional levels of statistical significance (p = 0.095).  The 
investigation concluded that tolvaptan provided a rapid and large therapeutic effect (d > .8) in 
psychotic patients.  This level of experimental control over serum sodium levels within the 
context of a randomized, placebo-controlled study should establish the necessary conditions to 
detect effects on cognitive and behavioral domains using the population being proposed.   
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 Thus the primary objective of the ongoing Tolvaptan for Hyponatremia study is to 
investigate the benefit of normalizing serum sodium on cognitive and behavioral function among 
schizophrenia patients with chronic hyponatremia.  This is being done within the framework of a 
randomized, double-blind, two-group comparison, in which half of the 20 patient sample of 
schizophrenic patients with chronic hyponatremia will be treated with tolvaptan and the other half 
will be treated with a matching placebo.  These will be patients who have a documented history 
of hyponatremia for a minimum of six months. 
 The hypothesis is that treatment with tolvaptan will not only normalize serum sodium 
levels in this population (defined as serum sodium > 135 mEq/L and < 145 mEq/L), but will also 
result in beneficial effects on cognitive and behavioral functioning.  
 While this larger study is focused on the effects normalized serum sodium on cognitive 
and behavioral functioning, the present thesis study is concerned with the construct of 
believability as it relates to positive psychotic symptom related distress.  The larger investigation 
simply provided de-identified data that made this research possible.  Below are the hypotheses 
generated for the present study on believability.     
1.7 Hypotheses 
 
The following hypotheses were made for the present investigation: 
 
(1) Positive symptom believability will mediate the effect of treatment condition (drug vs. 
placebo) on positive psychotic symptom-related distress.  In social and psychological 
research, mediation refers to a model in which a third variable represents the 
theorized mechanism through which an independent variable influences a dependent 
variable (Baron & Kenny, 1986; MacKinnin, Lockwood, Hoffman, & Sheets, 2002; 
Preacher & Hayes, 2008).  In the current study, we proposed that believability in 
positive symptoms is a variable through which the active drug tolvaptan influences 
positive symptom related distress (see Figure 1).  Previous research has demonstrated 
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that believability of hallucinations statistically mediates effects of a psychosocial 
treatment on hallucinated-related distress (Gaudiano et al., 2010).   
(2) Reductions in positive psychotic symptom believability will be associated with 
improved psychopathology.  As reported in Bach and Hayes (2002), lower 
believability was associated with a decreased need for rehospitalization at follow-up, 
reflecting a reduction in problematic symptomatology.  A second preliminary 
hypothesis is that change in believability will be negatively associated with change in 
positive symptomatology, as reflected in lower scores between baseline day 1, day 
30, and follow-up day 60 on the Psychotic Symptom Rating Scale (PSYRATS; 
(Drake, Haddock, Tarrier, Bentall, & Lewis, 2007) and Positive and Negative 
Syndrome Scale (PANSS; (Kay et al., 1987). 
(3) Theoretically relevant process variables will will change between Day 1, Day 30, 
and Day 60.  This hypothesis will evaluate change in all relevant process variables 
assessed by the PSYRATS and FBDH.  Process variables as used herin refer any 
potential mechanisms that would explain the effect of the treatment (i.e., tolvaptan) 
on symptom-related distress.  Though believability is hypothesized to be the mediator 
between the biological treatment and symptom-related distress, other potential 
variables will also be evaluated (e.g., hallucination frequency). 
Methods 
 
The pilot study that comprises this thesis was based on the clinical, Phase IV trial 
discussed below.  The clinical trial is ongoing, however de-identified data for the first 6 
participants was provided for this pilot study.  Furthermore, due to delays in recruitment the 
sample was too small to conduct the proposed statistical analyses; the available data were 
therefore examined using idiographic strategies.  Data will continue to be collected and final 
analyses will become a part of the Phase IV trial.  
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2.1 Overview 
 
The larger study is a Phase-IV, multi-site, randomized, double-blind, placebo-controlled, 
two-arm parallel study of the benefit of normalizing serum sodium on cognitive and behavioral 
measures in psychotic patients (Schizophrenia, Schizoaffective disorder, Delusional Disorder, 
Brief Psychotic Disorder, Major Depressive Disorder with psychotic features, Bipolar Disorder 
and Psychosis NOS) with chronic hyponatremia.  It is considered Phase IV because the active 
drug tolvaptan is already FDA approved for the treatment of clinically significant hypervolemic 
and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia 
that is symptomatic and has resisted correction with fluid restriction), including patients with 
heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH).  
However, it is unknown whether it will produce comparable benefits for the psychotic population 
comprising this study.  Thus, in accord with this study’s secondary objectives, as a Phase IV 
study there will be monitoring of drug-drug interactions (SAMSCA and antipsychotic etc.) as 
well as an examination of possible health benefits when correcting serum sodium in patients with 
psychotic disorders.  
The Commonwealth of Pennsylvania currently has 6 state psychiatric hospitals.  Each 
state hospital has 2-3 Long-Term Supervised Residences (LTSRs) affiliated settings.  This study 
has been approved by the Department of Public Welfare to recruit participants from any of these 
state hospitals, with each hospital reviewing and granting local IRB approval for the site.  It 
began recruitment at its home base, Norristown State Hospital, and is reaching out to the other 
hospitals as needed to complete the sample. 
 
2.2 Participants 
 
The total number of completed participants was 6 (4 active drug and 2 placebo).  
Inclusion criteria for the larger study were: Men or women between 18-65 years of age; 
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Psychiatric diagnosis of DSM-IV schizophrenia (any subtype), schizoaffective disorder, or 
psychosis NOS; Diagnosis of euvolemic hyponatremia (serum sodium < 133 mEq/L) for a 
minimum of 6 months; capacity to fully participate in the informed consent and HIPPA process, 
or have a legal guardian participate in the legal process; and willingness to be an inpatient for the 
duration of the study.  Formal exclusion criteria were: pregnant or breast-feeding women, or 
women planning to become pregnant or to breastfeed; overt symptoms of hyponatremia requiring 
immediate medical intervention (e.g., coma, seizures); acute or transient hyponatremia (e.g., 
associated with head trauma, postoperative state, or use of radiotherapy and/or chemotherapy); 
hyponatremia in hypovolemic states (e.g., due to fluid loss through vomiting, diarrhea, burns, 
etc.); hypovolemic hyponatremia is defined as the presence of clinical evidence of extracellular 
fluid volume depletion; hyponatremia in hypervolemic states (e.g., congestive heart failure); 
hypervolemia is defined as a presence of increased total body water with signs of edema; 
hyponatremia as a result of any medication that can safely be withdrawn; hyponatremia due to 
hypothyroidism or adrenal insufficiency; active psychogenic polydipsia; receiving within 7 days 
of enrollment other medication for treatment of hyponatremia, specifically: demeclocycline, 
lithium carbonate, urea, or any vasopressin antagonist; supine systolic arterial blood pressure of < 
90 millimeters of mercury (mmHg); serum creatinine > 3.0 mg/dL (> 265.2 mol/L); hypokalemia 
based on clinical sign/symptoms or lab findings (e.g., serum potassium < 3.5 mEq/L); 
uncontrolled diabetes mellitus; history of myocardial infarction within 30 days or active 
myocardialischemia at the time of enrollment; history of cerebral vascular accident (CVA) within 
30 days prior to screening; severe malnutrition (e.g., body mass index [BMI] < 17); advanced 
liver disease or documented diagnosis of cirrhosis or alcoholic hepatitis; urinary tract obstruction 
(benign prostatic hypertrophy [BPH] allowed if non-obstructive); history of chronic 
drug/medication abuse within the past 6 months or current alcohol abuse; terminally ill or 
moribund condition with little chance of short-term survival; receiving vasopressin or its analogs 
for treatment of any condition; known allergy to any vasopressin antagonist; recipient of any 
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investigational treatment within 30 days prior to baseline visit; unable to take oral medications; at 
serious suicidal risk. 
All participants were either inpatients residing in a Pennsylvania State psychiatric 
hospital or one of the affiliated LTSRs associated with the state hospital system.  The LTSRs are 
locked, community-based living arrangements with a 24-hour licensed nursing staff and medical 
and psychiatric attending physicians.  Importantly, the nursing staff dispenses all medications 
with accurate records maintained on a Medication Administration Record. 
The patient population consisted of 6 adults (1 female and 5 males) with a mean age of 
52 (SD=11.71) and ranging from 32 to 65 years old.  All participants were White; see Table 2 for 
additional demographic information. 
 The pilot study consisted of three assessment periods: screening (baseline), treatment, 
and follow-up.  The total study duration for each participant participating in all three periods was 
approximately 3 months.  Participants were randomized (1:1) on an inpatient basis to tolvaptan or 
matching placebo.  Study medication began at 15 mg per day, and was titrated up to 30 mg or 60 
mg per day.  Screening consisted of three baseline measures, with treatment continuing for 60 
days, and follow-up 30 days following the last dose. 
2.3 Measures 
2.3.1 Psychopathology 
The Positive and Negative Syndrome Scale (PANSS).  The PANSS (Kay et al., 1987) is 
commonly used for measuring symptom severity of patients with schizophrenia.  The scale has 
seven positive-symptom items, seven negative-symptom items, 16 general psychopathology 
symptom items, and thus constitutes four scales measuring positive and negative syndromes, their 
differential, and general severity of illness.  Each item is scored on the same seven-point severity 
scale.  In determining efficacy, a study of 101 schizophrenic patients found the four scales were 
normally distributed and supported their reliability and stability.  Furthermore, in a review of five 
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studies involving the PANSS, evidence of its criterion-related validity with antecedent, 
genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility 
for both typological and dimensional assessment (Kay et al., 1987).  
2.3.2 Believability and Distress 
The Psychotic Symptom Rating Scales (PSYRATS).  The PSYRATS (Drake et al., 2007) 
consists of two scales designed to rate auditory hallucinations and delusions.  The auditory 
hallucinations subscale (AH) is an 11 item scale, monitoring general symptom indices of 
frequency, duration, severity and intensity of distress and also symptom specific dimensions of 
controllability, loudness, location, negative content, degree of negative content, beliefs about 
origin of voices and disruption.  The delusions subscale (DS) is a six-item scale that assesses 
dimensions of delusions, including preoccupation, distress, duration, conviction, intensity of 
distress and disruption.  The PSYRATS has good inter-rater and retest reliability.  Validity is 
good, as assessed by internal consistency, sensitivity to change, and in relation to the PANSS.  
The current study proposes to use these scales to measure distress (in both amount and intensity) 
in relation to overall psychotic symptomatology.  Ratings will be collected at Day 1, Day 30, and 
follow-up Day 60. 
Frequency, Believability, and Distress of Hallucinations Rating Scale (FBDH).  The 
FBDH scale, modified from Bach and Hayes (2002) asks patients to rate the frequency, 
believability, and distress associated with their hallucinations.  Regarding frequency of 
hallucinations, participants will be asked: “On average, how often have you experienced [specific 
hallucination]?” 1 = never; 2 = less than once a week; 3 = about once a week; 4 = several times a 
week; 5 = daily; 6 = more than once a day; 7 = almost constant. Regarding believability of 
hallucinations, participants will be asked: “On a scale from 0 to 10, how much do you believe that 
[specific hallucination] is real or true? Zero means that you are certain it is not real or true, and 10 
means you are absolutely certain that it is real or true.”  Regarding distress associated with 
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hallucinations, participants will be asked: “On a scale from 0 to 10, how bothered are you by 
[specific hallucination]? Zero means not distressed at all and 10 means the most distressed you’ve 
ever been.”  Ratings will be collected at Day 1, Day 30, and follow-up Day.  This measure was 
successfully used in Gaudiano and Herbert (2006). 
2.3.3 Other Measures 
 Other measures used for the Tolvaptan for Hyponatremia study but not analyzed as part 
of the thesis include: the BACS (Keefe et al., 2004), the Wide Range Achievement Test (WRAT) 
(Bijou & Jestak, 1941), the Simpson- Angus Rating Scale (SAS) (Simpson & Angus, 1970), and 
the Trail-Making Test (TMT) (Trails A & B) (Reitan, 1958). 
2.4 Procedures 
 
Approval from the Norristown State Hospital Institutional Review Board was obtained.  
Approval from Drexel University’s Institutional Review Board was obtained in the form of a 
Category 4 approval. 
Dr. Richard Josiassen obtained informed consent from all participants prior to 
enrollment.  A lab assistant entered all data into a secure, online database.  De-identified 
information was provided for analysis. 
All assessors were blind to treatment condition.  After completing the BACS and PANSS 
assessments on days 1, 30, and 60, the assessor administered the three additional questionnaires, 
starting with both PSYRATS questionnaires and ending with the FBDH questionnaire.  The time 
required for the administration of three additional questionnaires was approximately 30 minutes.   
Results 
 
 Considering that the final sample size did not reach the intended number of 20 
participants, mediation analyses could not be conducted, nor could we formally evaluate the other 
study hypotheses.  Descriptive statistics are reported, and individual and group scores were 
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graphed over time in an effort to identify trends between participants on active drug and those on 
placebo.  All individual graphed scores represent raw data, with the exception of the Frequency, 
Believability and Distress of Hallucinations scale (FBDH).  Graphed group results use mean 
scores. 
Concerning FBDH scale, due to its combination of Likert and interval scales, FBDH 
individual scores were converted to Z-scores for comparison purposes.  On the frequency of 
hallucinations sub-item of the FBDH scale, a score of 1 on the interval scale is equivalent to a Z-
score of .22 (i.e., both equate to no hallucinatory experiences).  A score of 7, the highest on this 
sub-dimension, equates to a Z-score of .96 (i.e., hallucinations occur almost constantly).  On the 
believability and distress of hallucinations Likert sub-items of the FBDH scale, a score of 0 is 
equivalent to a Z-score of .15 (i.e., absolute certainty that hallucinations are not true or real; not 
distressed at all).  Though the language is suggestive of hallucinatory experiences, we take a 0 on 
these sub-dimensions to suggest no hallucinatory behavior was present the week prior and up to 
the time of the interview.  A score of 10 – the highest score attainable – is equivalent to a Z-score 
of .96 (i.e., absolute certainty that hallucinations are true or real; the most distressed you have 
ever been). 
 
3.2 Description of Individual Participants 
 
Participant 1 is a 60-year-old single, white male.  His Axis I diagnosis is Schizophrenia, 
Paranoid Type (295.30).  He currently lives in a long-term care facility in rural Pennsylvania. 
Participant 1 was on active drug. 
Participant 2 is a 32 year-old single, white male.  He is an inpatient at a state psychiatric 
hospital in rural Pennsylvania.  His Axis I diagnoses are Impulse-control disorder (NOS) 
(312.01); Attention deficit hyperactivity disorder combined type by history (314.01); Paraphilia 
(NOS) by history; and Nicotine dependence (305.1).  Participant 2 was on placebo. 
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Participant 3 is a 65 year-old divorced, white female.  She is an inpatient at a state 
psychiatric hospital in rural Pennsylvania.  Her Axis I diagnosis is Bipolar I Disorder, Most 
Recent Episode, Manic, Severe with Psychotic Features (269.44).  Participant 3 was on active 
drug.  
Participant 4 is a 53 year-old, white male.  He is an inpatient at a state psychiatric hospital 
in rural Pennsylvania.  His Axis I diagnoses are Schizoaffective Disorder, Bipolar Type (295.70). 
Participant 4 was on active drug.  
Participant 5 is a 46 year-old, white male.  He is an inpatient at a state psychiatric hospital 
in rural Pennsylvania.  His Axis I diagnosis is Delusional Disorder (297.1).  Participant 5 was on 
placebo. 
Participant 6 is a 56 year-old, white male.  He is an outpatient living in a long-term care 
facility in rural Pennsylvania.  His Axis 1 diagnosis is Schizophrenia, Paranoid Type (295.30). 
Participant 6 was on active drug. 
 
3.3 Individual Results 
 
 All individual graphs have been provided and can be found following the discussion. 
Means and standard deviations for each instrument for each participant (see Table 1) can be 
found following the discussion section.  
3.3.1 Participant 1 
PSYRATS auditory hallucinations subscale total scores decreased from 29 points on day 
1, to 26 points on day 30, and to 25 points on 60 day.  On the believability item of the PSYRATS 
auditory hallucinations subscale, believability scores decreased from 4 points on day 1 (i.e., 100% 
conviction that the voices are externally generated) to 3 points on days 30 and 60 (i.e., !50% 
conviction but < 100%).  No distress associated with auditory hallucinations was reported 
between days 1, 30, and 60. 
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On the PANSS hallucinatory behavior item, scores decreased from 6 (i.e., severe, 
hallucinations are present almost continuously, causing major disruption of thinking and 
behavior.  Patient treats these as real perceptions, and functioning is impeded by frequent 
emotional and verbal responses to them) on day 1 to 5 (i.e., moderate-severe, hallucinations are 
frequent, may involve more than one sensory modality, and tend to distort thinking and/ or 
disrupt behavior.  Patient may have delusional interpretation of these experiences and respond to 
them emotionally and, on occasion, verbally as well) on day 60. No day 30 PANSS data were 
available for Participant 1.  
On the FBDH scale, frequency of hallucinations dropped slightly from a 7/ .96 (i.e., 
hallucinations occur almost constantly) on day 1, to a 6/ .91 (i.e., hallucinations occur more than 
once a day) on day 30. By day 60, scores matched day 1 levels.  
Believability followed a similar trend, decreasing from a 10/ .93 (i.e., absolute certainty 
in the validity of hallucinations) on day 1, to a 9/ .90 (i.e., near absolute certainty in the validity of 
hallucinations) on day 30. By day 60, scores increased again to day 1 levels.  
Distress dropped slightly from a 4/ .85 (i.e., mild distress concerning hallucinatory 
experience) on day 1 to 3/ .72 (i.e., little distress concerning hallucinatory experience) on day 30. 
On day 60, scores increased to 7/ .99 (i.e., moderate-sever distress).  
 Regarding PSYRATS delusions subscale total scores, scores increased from 14 on day 1, 
to 15 on day 30, reaching 17 by day 60.  On the conviction item of the PSYRATS delusions 
subscale, Participant 1 maintained 100% conviction in his delusions, sustaining a 4 (i.e., 
conviction is 100%) during the 60-day treatment period.  Distress over the treatment period 
remained minimal.  
 On the PANSS delusion item, scores decreased from 7 (i.e., extreme, presence of a stable 
set of delusions which are either highly systematized or very numerous, and which dominate 
major facets of the patient’s life.  This frequently results in inappropriate and irresponsible action, 
which may even jeopardize the safety of the patient or others) on day 1 to 6 (i.e., severe, presence 
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of stable set of delusions which are crystallized, possibly systematized, tenaciously held, and 
clearly interfere with thinking, social relations, and behavior) on day 60.  No day 30 PANSS data 
were available for Participant 1.  
 Results for Participant 1 do not support study hypotheses.  There were no clinically or 
statistically significant changes in hallucinations or delusions over the 60-day treatment.  
Furthermore, there was no significant change regarding frequency, believability, or distress.  With 
this said, the elevated level of distress reported on day 60 on the PSYRATS instrument will be 
addressed in the discussion. 
3.3.2 Participant 2 
 Participant 2 did not report any auditory hallucinations.  However, he did report olfactory 
hallucinations on days 1 and 60, and was given a PANSS hallucinatory behavior item scores of 5 
(i.e., moderate severe, hallucinations are frequent, may involve more than one sensory modality, 
and tend to distort thinking and/ or disrupt behavior.  Patient may have delusional interpretations 
of these experiences and respond to them emotionally and, on occasion, verbally as well) and 4 
(i.e., moderate, hallucinations occur frequently but not continuously, and the patient’s thinking 
and behavior are affected only to a minor extent) respectively.  No day 30 PANSS data were 
available for Participant 2. 
 On the FBDH scale, frequency of hallucinations scores were 5/ .82 (i.e., hallucinations 
occur daily) on day 1, 1/ .22 (i.e., hallucinations have not occurred during the past week) on day 
30, and 4/ .69 (i.e., hallucinations occur several times a week) on day 60. 
 Believability follows a similar pattern with a score of 6/ .71 (i.e., slightly > 50% certainty 
that hallucinations are true or real) on day 1, 0/ .19 (i.e., hallucinations have not occurred) on day 
30, and 7/ .79 (i.e., moderate certainty, > 75% certainty that hallucinations are true or real) on day 
60. 
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 Distress scores were 5/ .93 (i.e., mild-moderate distress over hallucinatory experiences) 
on day 1, 0/ .22 on day 30, and a 5/ .93 (i.e., mild-moderate distress over hallucinatory 
experiences) on day 60. 
PSYRATS delusions subscale total scores increased from a 0 on day 1, to 7 on day 30, 
and to 8 on day 60.  On the conviction item of the PSYRATS, Participant 2 was given a 0 on day 
1, and a 2 on days 30 and 60 (i.e., there is some doubt relating to conviction in beliefs, between 
10-49%).  On the distress item of the PSYRATS delusions subscale, distress increased from 0 on 
day 1, to 1 on days 30 and 60.  
 On the PANSS delusions item, Participant 2 was given a score of 2 on day 1 (i.e., 
minimal, questionable pathology; may be at the upper extreme of normal limits) and a 3 on day 
60 (i.e., mild, presence of one or two delusions, which are vague, uncrystallized, and not 
tenaciously held.  Delusions do not interfere with thinking, social relations, or behavior).  No day 
30 PANSS data were available for Participant 2. 
  Results for Participant 2 do not support study hypotheses.  There were no clinically or 
statistically significant changes in hallucinations or delusions over the 60-day treatment.  
Furthermore, there was no significant change regarding frequency, believability, or distress. 
3.3.3 Participant 3 
No hallucinations or delusions were reported.  Minimal delusional ideation was reported 
on day 30 on the PANSS; however, a score of 2 indicates thinking of questionable pathology that 
may be at the upper extreme of normal limits.  There are no other scores to report.  
Results for Participant 3 do not support study hypotheses.  There were no clinically or 
statistically significant changes in hallucinations or delusions over the 60-day treatment.  
Furthermore, there was no significant change regarding frequency, believability, or distress. 
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3.3.4 Participant 4  
Participant 4 did not report hallucinatory behavior on days 1 and 60 for any hallucination 
scale.  On Day 30 however, he did report hallucinatory behavior and was given a score of 8 on 
the PSYRATS auditory hallucinations subscale, which indicates minimal hallucinatory behavior.  
On the believability item of the PSYRTS auditory hallucinations subscale, days 1 and 60 were 
given 0s reflecting an absence of hallucinatory experiences.  Participant 4 was given a score of 2 
(i.e., believes voices to be solely internally generated and related to the self) on day 30.  
Participant 4 did not report any distress during the 60-day treatment period. 
 There is a similar pattern on the PANSS hallucination item.  On day 1, Participant 4 
reported no hallucinations of any modality.  On day 30, he received a PANSS score of 3 (i.e., one 
or two clearly formed but infrequent hallucinations, or else a number of vague abnormal 
perceptions, which do not result in distortions of thinking or behavior).  This mild hallucinatory 
behavior persisted and on day 60, Participant 4 was given a PANSS score of 3 (i.e., one or two 
clearly formed but infrequent hallucinations, or else a number of vague abnormal perceptions, 
which do not result in distortions of thinking or behavior), indicating hallucinations in a modality 
other than auditory. 
 On the FBDH scale, all three items followed a similar trend.  On the frequency item, 
Participant 4 was given a score of 1/ .22 (i.e., no hallucinatory behavior) on day 1, 4/ .69 (i.e., 
hallucinations occur several times a week) on day 30, and 1 on day 60.  
On the believability item, Participant 4 was given scores of 0/ .19 on day 1, a 4/ .53 (i.e., 
< 50% certainty hallucinations are real or true) on day 30, and a 0/ .19 on day 60.  
No distress was reported associated with hallucinatory behavior during the 60-day 
treatment period. 
Delusional behavior was the inverse of the reported hallucinatory behavior.  On day 1, 
Participant 4 was given a PSYRATS delusions subscale total score of 8 points.  By day 30, he did 
not report any delusions from the previous week up until the time of interview.  By day 60, 
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however, he was again given a score of 8 points.  On the conviction item of the PSYRATS 
delusions scale, Participant 4 was given a score of 2 (i.e., holds <50% conviction that voices 
originate from external causes) on day 1, a 0 on day 30, and a 2 on day 60.  On the distress item 
of the PSYRATS delusion subscale, Participant 4 was given a score of 2 (i.e., beliefs caused 
distress on approximately 50% of occasions) on day 1, a 0 on day 30, and a 1 (i.e., distress was 
felt on a minority of occasions) on day 60.  
 On the PANSS delusions item, scores decreased from a 3 (i.e., mild, presence of one or 
two delusions, which are vague, uncrystallized, and not tenaciously held.  Delusions do not 
interfere with thinking, social relations, or behavior) on day 1, to a 1 (i.e., absent, definition does 
not apply) on day 30.  By day 60, scores had increased slightly to a 2 (i.e., minimal, questionable 
pathology; may be at the upper extreme of normal limits). 
 Though Participant 4 did report both delusions and hallucinations over the 60-day 
treatment period, results do not support study hypotheses.  There were no clinically or statistically 
significant changes in symptoms over the 60-day treatment.  Furthermore, there was no 
significant change regarding frequency, believability, or distress. 
3.3.5 Participant 5 
 Participant 5 did not report any hallucinatory behavior in any modality.  He reported 
delusional ideation on day 1, and was given a total PSYRATS delusions subscale score of 5.  On 
the sub-item of this scale, he was given a score of 1 for both conviction and distress (i.e., very 
little conviction in reality of beliefs, less than 10%, and these beliefs caused distress on a minority 
of occasions).  However, on day 30 and day 60, Participant 5 did not report delusional beliefs.  
 Results for Participant 5 do not support study hypotheses.  There were no clinically or 
statistically significant changes in hallucinations or delusions over the 60-day treatment.  
Furthermore, there was no significant change regarding frequency, believability or distress. 
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3.3.6 Participant 6 
Participant 6 demonstrated a pattern of decreased hallucinatory behavior over the course 
treatment.  On the PSYRATS auditory hallucinations subscale, Participant 6 was given a score of 
22 on day 1, a 14 on day 30, and a 0 on day 60 (i.e., no were present the previous week and up to 
the day of the interview).  On the believability item of the PSYRATS auditory hallucinations 
subscale, Participant 6 was given a score of 4 (i.e., believes voices are solely due to external 
causes (100 % conviction)) on day 1, a 2 (i.e., holds <50% conviction that voices originate from 
external causes) on day 30, and a 0 on day 60.  On the distress item of the PSYRATS auditory 
hallucination scale, Participant 6 was given a score of 1 on day 1 (i.e., voices occasionally 
distressing, majority not distressing (<10%)), a 1 on day 6, and a 0 on day 60. 
On the PANSS hallucinatory behavior item, scores decreased from a 4 (i.e., moderate, 
hallucinations occur frequently, but not continuously, and the patient’s thinking and behavior are 
affected only to a minor extent) on day 1, a 3 (i.e., mild, one or two clearly formed but infrequent 
hallucinations) on day 30, to a 2 (i.e., minimal, questionable pathology; may be at the upper 
extreme of normal limits) on day 60. 
On frequency item of the FBDH scale, Participant 6 was given a score of 5/ .82 (i.e., 
hallucinations occur daily) on day 1, and a 2/ .36 (i.e., hallucinations occur less than once a week) 
on days 30 and 60.  
On the believability item of the FBDH scale, Participant 6 was given a score of 7/ .79 
(i.e., moderate certainty, > 75% conviction in the reality or truthfulness of hallucinations) on day 
1, a 6/ .71 (i.e., slightly > 50% certainty that hallucinations are true or real) on day 30, and a 7/ 
.79 on day 60. 
On the distress item of the FBDH scale, Participant 6 was given a score of 3/ .72 (i.e mild 
distress over hallucinatory experiences) on day 1, 2/ .55 (i.e., minimal distress over hallucinatory 
behavior) on day 60, and 2/ .55 on day 60,  
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PSYRATS delusions subscale total scores initially dropped from an 11 on day 1, to an 8 
on day 30.  On day 60, however, Participant 6 was given a score of 13.  This initial drop followed 
by an increase in delusional behavior is also reflected in delusional conviction sub-dimensions.  
Participant 6 was given a 3 on day 1 (i.e., conviction in belief is very strong, between 50-99%) 
followed by a 2 on day 30 (i.e., some doubts relating to conviction in beliefs, between 10-49%).  
On day 60, conviction is back to a 3.  On the distress item, Participant 6 was given a score of 1 on 
days 1 and 30 (i.e., beliefs cause distress on the minority of occasions), and a 2 (i.e., beliefs cause 
distress on approximately 50% of occasions) on day 60. 
 On the PANSS delusions item, scores initially decreased from a 4 (i.e., moderate, 
presence of either a kaleidoscopic array of poorly formed, unstable delusions) on day 1, to 3 (i.e., 
mild, presence of one or two delusions, which are vague, uncrystalized, and not tenaciously held) 
on day 30, but elevated back to a 4 on day 60. 
 Due to limited data, it is uncertain whether or not these results confirm study hypotheses. 
Participant 6 reported clinically significant reductions in the frequency of auditory hallucinations.   
However, he did not report reductions in the believability of his hallucinations.  Therefore, these 
data do not confirm hypotheses 1 or 2, but potentially confirm hypothesis 3.  A re-analysis of 
these results will be made upon completion of all 20 participants. 
3.4   Group Results 
   
 Mean group scores (see table 1) for all participants in both active drug and placebo 
groups were graphed.  On the PSYRATS total auditory hallucinations sub-scale, active drug 
group scores decreased between days 1, 30, and 60: M=12.75 (SD=14.99), M=12.0 (SD= 10.96), 
and M=6.25 (SD=12.50) respectively.  Placebo group scores remained 0 over the 60-day trial. For 
those on Placebo, no auditory hallucinations were reported, though hallucinations in other 
modalities were reported.  This result will be addressed in the discussion.   
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 On the believability item of the PSYRATS auditory hallucinations subscale, active drug 
group scores on between days 1, 30, and 60 were M=2.0 (SD=2.39), M=1.75 (SD=1.26), and 
M=0.75 (SD=1.5) respectively.  Distress scores associated with auditory hallucinations for active 
drug participants between days 1, 30, and 60 were M=0.5 (SD=0.57), M=0.5 (SD=0.57), and 
M=0.25 (SD=0.5) respectively.  Placebo group scores over the 60-day trial for both believability 
and distress measures were 0.   
 On the PANSS positive scale (a 7-item sub-set of the PANSS with a total possible score 
of 49), active drug group scores between days 1 and 60 (excluding day 30 due to incomplete data) 
were M=17.25 (SD=9.77) and M=17.25 (SD=7.80) respectively.  Placebo group scores between 
days 1 and 60 were M=11 (SD=4.24) and M=11 (SD=5.65) respectively.  On the PANSS 
hallucinatory behavior individual item, active drug group mean scores decreased slightly between 
days 1 and 60: M=3 (SD=2.45) and M=2.75 (SD=2.22) respectively.  Placebo group scores also 
saw a slight reduction between days 1 and 60: M=3 (SD=2.83) and M=2.5 (SD=2.12) 
respectively.  
 On the frequency item of the FBDH scale, active drug group scores between days 1, 30, 
and 60 were M=0.555 (SD=0.391), M=0.545 (SD=0.313), and M=0.440 (SD=0.352) respectively. 
Placebo group scores between days 1, 30, and 60 were M=0.520 (SD=0.424), M=0.220 (this score 
equates to a 0), and M=0.455 (SD=0.332) respectively.  
 On the believability item of the FBDH scale, active drug group scores between days 1, 
30, and 60 were M=0.533 (SD=0.402), M=0.583 (SD=0.302), and M=0.525 (SD=0.391).  Placebo 
group scores between days 1, 30, and 60 were M=0.450 (SD=0.367), M=0.190 (this score equates 
to a 0), and M=0.490 (SD=0.424). 
 On the distress item of the FBDH scale, active drug group scores between days 1, 30, and 
60 were M=0.503 (SD=0.330), M=0.428 (SD=0.250), and M=0.495 (SD=0.365) respectively.  
Placebo group scores between days 1, 30, and 60 were M=0.575 (SD=0.502), M=0.220, and 
M=0.575 (SD=0.502) respectively.  
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 On the PSYRATS total delusions sub-scale, active drug group scores fluctuated between 
days 1, 30, and 60: M=8.25 (SD=6.021), M=5.75 (SD=7.23), and M=9.5 (SD=7.33) respectively. 
Placebo group scores increased slightly between days 1, 30, and 60: M=2.5 (SD=3.54), M=3.5 
(SD=4.95), and M=4 (SD=5.66). 
 On the conviction sub-item of the PSYRATS total delusions sub-scale, active drug group 
scores between days 1, 30 and 60 were M=2.25 (SD=1.71), M=1.5 (SD=1.92), and M=2.25 
(SD=1.71) respectively.  Placebo group scores increased slightly on the conviction sub-item, from 
M=0.5 (D=0.707) on day 1 to M=1.0 (SD=1.41) on days 30 and 60.  On the distress sub-item, 
active drug group scores were minimal: M=1 (SD=0.816), M=0.5 (SD=0.577), and M=1 
(SD=0.816).  The placebo group did not report any distress. 
 On the PANSS delusion item, active drug group scores decreased slightly between days 1 
and 60: M=3.75 (SD=2.50) and M=3.25 (SD=2.217) respectively.  Placebo group scores increased 
slightly between days 1 and 60: M=1.5 (SD=0.707) and M=2 (SD=1.414) respectively. 
Discussion 
 
 This pilot study intended to assess positive symptom believability as a mediator between 
treatment condition (drug vs. placebo) and positive psychotic symptom-related distress in patients 
diagnosed with Schizophrenia, Schizoaffective disorder, Delusional Disorder, Brief Psychotic 
Disorder, Major Depressive Disorder with psychotic features, Bipolar Disorder and Psychosis 
NOS.  Due to small sample size at time of this analysis, there were not enough data to complete 
formal mediation statistics or to evaluate formally the other study hypotheses.  Furthermore, there 
was no visible treatment effect between active drug and placebo group participants.  Given this, it 
becomes difficult to evaluate all hypotheses because without a treatment effect, there is no 
mediation.  Therefore, any insight gleaned from reported individual and group results is 
observational, and any implications should be considered as speculative.  All results will be 
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reconsidered within the framework of the originally proposed statistical analyses once all 20 
participants have completed treatment. 
4.1   Trends and Observations 
4.1.1 Individual Results 
 It is important to note a few trends and points of interest these data did produce that move 
in the direction of the proposed hypotheses.  Experienced clinicians who work with chronic 
psychotic populations would regard a 25% improvement in symptom severity at post-treatment 
on the PANSS and PSYRATS as meaningful (Durham et al., 2003); a 50% improvement at post-
treatment would be considered an important clinical change (Durham et a., 2003; Kuipers, et al., 
1997; Sensky et al., 2000; Tarrier et al., 1992).  Only Participant 6 appeared to make such an 
improvement.  Participant 6 saw a 2-point reduction between days 1 and 60 on the PANSS 
hallucinatory behavior measure. This reduction was from a moderate level of hallucinatory 
behavior to a minimal level (i.e., at the upper limits of normal).  Additionally, Participant 6 saw a 
22-point reduction in reported auditory hallucinations, representing a 100% reduction in auditory 
hallucinations as measured by the PSYRATS auditory hallucinations scale.  Furthermore, though 
Participant 6 reported clinically significant reduction in the frequency of hallucinatory symptoms 
and a modest reduction in distress as measured by the FBDH scale, there was no reduction in 
believability.  Therefore, it is uncertain whether or not these data reflect a treatment effect 
because while he was the only participant in the active drug group to report such significant 
reductions in symptoms, he did not report a change in believability.  
It is also noteworthy to mention a possible pattern between those with an Axis I diagnosis 
in the schizophrenia spectrum and a reduction in overall hallucinatory behavior and/ or an 
increase in delusional ideation.  For participants with an Axis I diagnosis of Schizophrenia (i.e., 
Participants 1 and 6), there was a mutual pattern of decreased hallucinatory behavior on all three 
measures over the 60-day treatment period.  Similarly, there was a pattern of increased delusional 
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ideation over the 60-day treatment period.  Also, for both participants, believability scores either 
decreased or remained unchanged.  In terms of amount of distress, there was no change between 
baseline and follow-up for Participant 6. 
Participant 1, however, did report increased levels of distress on day 60. It was reported 
by nurses that Participant 1 became more “demanding” and “uncooperative” as treatment 
progressed.  Though this could be interpreted as a manifestation of worsening symptomology, it 
has been argued in the quality of life literature that psychotic patients with renewed insight might 
realize their life-restrictions more clearly.  The stigma of being mentally ill and being hospitalized 
can lead to any number of behaviors, from depressive to increased risk of suicidality (Karow & 
Pajonk, 2006).  
Participant 4 (active drug), whose primary Axis I diagnosis is Schizoaffective disorder, 
Bipolar type, had a distinct pattern of inverse symptom reporting.  Perhaps a result of the 
affective nature of his diagnosis, on days where there were no reports of hallucinatory behavior 
there were distinct increases in delusional ideation.  Inversely, on days with no delusional 
ideation, there were reports of hallucinatory behavior.  Believability scores matched this pattern 
of behavior.  On days when hallucinatory behavior was reported, believability in such 
hallucinations, though mild, was reported.  Similarly, when delusional ideation was reported, 
conviction in such delusions was also reported.  Overall, however, the frequency and intensity of 
these symptoms were mild and were not clinically or statistically significant.,  
As for participants with other Axis I diagnoses, results were less clear.  For Participant 2 
(placebo), whose primary Axis I diagnosis is Impulse-control disorder, it was difficult to 
understand his pattern of symptom reporting, which vacillated during the 60-day treatment 
period.  No auditory hallucinations were reported over the 60-day treatment period.  Olfactory 
hallucinations were reported, however.  From reading the PANSS interview, it was apparent the 
olfactory hallucinations were of women’s perfume and smells of females in his room.  It is 
possible that the olfactory hallucinations and reported delusional ideation had to do with his 
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diagnosis of Paraphilia (NOS) by history.  There was also a significant amount of distress 
reported on days 1 and 60 when olfactory hallucinations were present.  Believability in 
hallucinations also slightly increased during treatment.  With this said, it is difficult to make any 
statement about these symptoms other than it appeared Participant 2 worsened over the course of 
treatment.  
Participant 3 (active drug), whose primary Axis I diagnosis is Bipolar I Disorder, Most 
Recent Episode, Manic, Severe with Psychotic Features, did not present with psychosis during the 
60-day treatment period.  Implications of this are discussed in the below Methodological 
Concerns section.  
Participant 5 (placebo), whose primary Axis I diagnosis is Delusional disorder, reported 
mild delusions only on day 1.  No hallucinatory behavior of any kind was reported. Again, 
implications of this are discussed below. 
4.1.2 Group Observations 
The group data neither add nor detract from the individual reports.  For the active drug 
group, there is a reduction in hallucinatory behavior and a mild increase in delusional ideation, 
similar to individual results.  The same can be said for measures of believability and distress, 
where there are relatively low and unchanging patterns of belief or conviction in psychotic 
symptoms, and relatively low levels of distress.  For those on placebo, only Participant 2 reported 
hallucinatory behavior or delusional beliefs, thus making the placebo group data a mere reflection 
of one participant.  
4.2 Methodological Concerns 
 
In reporting group data, a few issues arose attributable to the inadequate and unbalanced 
sample population that render the group data unhelpful to the overall picture.  First, as indicated 
above, Participants 2, 3, and 5 do not have diagnoses within the schizophrenia spectrum 
disorders.  Only Participant 2 – who represents one half of the placebo group – reported psychotic 
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symptoms.  This precludes head-to-head statements concerning these two groups.  Of those in the 
active drug group, only Participant 6 saw what would be considered clinically significant 
improvement.  Yet, because participants on active drug (with the exception of Participant 3) had 
diagnoses within the schizophrenia spectrum, group results still resembled individual results.  
Therefore, reporting group data at this stage, and for such a small sample, only muddies the 
already murky results.  
The second noteworthy concern is with the instruments used to detect psychosis. 
Instruments such as the PANSS are essential for assessing global outcome.  However, they were 
not primarily designed to elicit information on, and measure the severity of, different dimensions 
of a particular symptom (e.g. hallucinatory believability, loudness of voices).  As such, these 
types of assessments are less equipped to monitor changes in the severity of symptoms over time 
and to register information as to how symptom dimensions co-vary as a result of treatment 
(Haddock et al., 1999).   
Thus, instruments such as the PSYRATS and the FBDH scales are useful supplemental 
tools.  However, the PSYRATS is dependent on the presence of auditory hallucinations; it does 
not monitor other modalities of hallucinatory behavior.  Thus, if hallucinatory behavior is present, 
but fixed to a modality other than auditory, only the PANSS and the supplemental FBDH scales 
will detect it.  This can become a hindrance when trying to measure all dimensions of psychotic 
behavior over time.  For this project, there were instances when data on the PANSS reflected 
hallucinatory behavior, but there was no supplemental PSYRATS data to describe other 
dimensions of the hallucinatory behavior.  For example, when the graphs are observed for 
Participant 2, one might notice what appears to be a disparity between PSYRATS auditory 
hallucinatory behavior scores of zero, and both PANSS scores that decrease from 5 points to 4 
points between days 1 and 60, and FBDH scores that increase from .71 to .79 between days 1, 30, 
and 60.   Ostensibly, this looked like a reliability issue.  However, upon inspection of the PANSS 
interview, Participant 2 reported olfactory hallucinations that were not monitored by the 
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PSYRATS.  Again, without supplemental interview data, this could have contributed to a 
significant amount of unexplained variance.  Therefore, though the PSYRATS is an excellent 
supplemental tool, additional scales might be necessary to address changes in symptom 
dimensions within the full spectrum of positive psychotic behavior.  
4.3 Strengths and Weaknesses 
 
 A major strength of this study is that it is using tolvaptan to treat hyponatremia.  In the 
seminal SALT trial (Shrier et al., 2006), the efficacy of tolvaptan over placebo was demonstrated 
by significant improvement in sodium from baseline to Day 4 and Day 30.  Beginning at Day 2, 
results for all comparisons confirmed the efficacy of tolvaptan over placebo.  Measurements after 
8 hours of receiving tolvaptan were even marginally improved.  Furthermore, as hyponatremia 
affects the brain globally and can lead to CNS manifestations, it is plausible that even mild 
hyponatrmeia could result in subtle impairments of both cognitive and motor functioning, 
especially in compromised populations.  Josiassen et al (2010) demonstrated in a subgroup of 
schizophrenic patients (n=9) from the SALT trial, cognitive improvements were associated with 
improved serum sodium that nearly achieved statistical significance (p=0.095).  
Another strength was the use of idiographic strategies to portray the data.  Although 
comparing aggregated data from groups of individuals is the common practice, there are 
limitations to the efficiency and flexibility of such methodologies.  Furthermore, there are 
limitations to the generality of their results (Barlow & Nock, 2009).  Clearly, as this study 
demonstrates, group statistics whether formal or, in this case, informal, can overlook individual 
variations in both treatment-related symptom change and response (Taylor & Weems, 2011; 
Barlow & Nock, 2009; Kazdin, 2008).  
 A major disadvantage of this study is availability of the patient population.  Though 
hyponatremia is a common comorbidity in psychiatric populations (Josiassen et al., 2010), due to 
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restrictions on state hospital funding and subsequent patient population reductions, finding 
patients who fit inclusion criteria proved to be a major obstacle.  
4.4 Summary and Concluding Remarks 
 
Despite the major hindrance of having a small, underpowered, and unbalanced data set, 
there are glimmers of promise within this project.  A point of paramount importance is the 
similarity between the two participants with schizophrenia (i.e., Participants 1 and 6).  Both 
patients did report reductions in psychopathology.  Participant 6 also reported clinically 
significant reductions.  For the remaining four participants, it is difficult to assess their data due to 
their relative obscurity.  Participant 4, though on active drug, reported worsening 
psychopathology yet maintained low levels of believability.  However, his worsening 
psychopathology was not clinically significant.  Participant 2, though on placebo, got 
progressively worse, though again, it was not clinically significant.  For the other two 
participants, their psychopathology neither improved nor worsened; in fact, it appears it never 
manifested over the course of the 60-day treatment.  Therefore as a whole, these data are very 
noisy.  Idiographically, however, these data do highlight a relationship between psychopathology 
and believability, though the study limitations preclude further conclusions. 
Since the publication of the PSYRATS (Haddock et al., 1999a), there have been many 
published studies using the instrument (Drake et al., 2007; Durham, Guthrie, Morton, Reid, & 
Treliving, 2003; Thomas, Rossell, Farhall, Shawyer, & Castle, 2011; Valmaggia, Van Der Gaag, 
Tarrier, & Pijnenborg, 2005). However, many have been to assess the effectiveness of CBT for 
treating psychosis.  This project was developed out of an effort to cross levels of analysis (i.e., 
studying psychosocial variables as mechanisms of biological treatment effect, or vice versa) 
within one treatment study.  No previous clinical trial of a biological treatment has examined 
psychological mediators of treatment effects on psychotic symptom outcomes.  Furthermore, 
while the research of Gaudiano et al. (2010) along with the treatment study of Bach and Hayes 
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(2002) indicate constructs such as believability to be an important factor in acceptance-based 
behavior therapy for psychosis, it is still not known whether such constructs are only operative for 
psychosocial treatments which directly target them, or if these constructs are common pathways 
through which multiple interventions might also operate.  Thus, future directions for this project 
are to revisit study hypotheses once all 20 participants have completed.  
A better understanding of how symptom dimensions change as a result of a biological 
treatment would be invaluable for assessing outcome and for tailoring both medication and 
clinical treatment to individual patients.  The assessments used in this study, specifically the 
PSYRATS auditory hallucinations scale, could be improved to manage the diversity within 
positive psychotic symptoms (e.g., distress).  However, there are two issues limiting the 
sensitivity of the assessment: (1) not all patients with a schizophrenia spectrum disorder report 
hallucinations, and (2) even among those who do report hallucinations, their presence and type 
(i.e., auditory, olfactory, visual, gustatory, or tactile) may vary over the course of the illness.  As a 
corollary, if symptoms are not present, there can be no distress over those symptoms.  
Alternatively, if symptoms are present and continuous, they can become a part of the internal 
milieu, rendering them unquestionable and potentially devoid of subjective distress.  In both 
cases, distress is limited, but by different factors.  It becomes important to have an assessment 
that can both differentiate between hallucinatory modalities, and once identified, provide a multi-
dimensional assessment of the symptoms.  Regarding the assessments used in this study, the 
PSYRATS auditory hallucinations scale was perhaps too specific in its focus.  It assessed 
auditory hallucinations in isolation, neglecting other hallucinatory activity and potential distress.  
It also neglected potential anticipatory distress over a reoccurrence of auditory hallucinations.  
Therefore, future studies should either refine the PSYRATS or develop additional rating scales 
either supplemental to the PSYRATS or in addition to it, to refine the instruments’ sensitivity and 
assess symptom dimensions of other hallucinatory modalities. 
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 Drake et al. (2007) examined the psychometric properties of the PSYRATS to assess 257 
first-episode suffers (119 were followed at six weeks).  It was determined that the PSYRATS had 
good reliability and validity in first episode samples and complemented existing measures of 
outcome like the PANSS.  Therefore, it might be beneficial to use this instrument in future studies 
with other detailed measures of specific target symptoms to explore the relationship between 
believability and psychopathology in both chronic and acute first-episode schizophrenic 
populations.   
The group that comprised this study included chronic populations, either as inpatients in a 
state hospital or outpatients in monitored, long-term care facilities.  In this chronic state, 
delusions and hallucinations tend to appear as familiar, fixed, unchallengeable, unassailable 
truths.  The distress that would have accompanied these symptoms upon first appearance has 
often significantly dissipated.  Conversely, for those suffering from acute symptoms, 
hallucinations and delusions represent more novel experiences, and may therefore be more 
distressing.  
This distinction might be a valid argument for why there was less reported distress within 
this study’s population compared to prior ACT studies (i.e., Bach and Hayes, 2002; Gaudiano and 
Herbert, 2006; Gaudiano, Herbert, and Hayes, 2010) that used acute outpatients.  Two cases 
deserve mention on this point.  Participant 1, a 60-year old male diagnosed with schizophrenia, 
with persistently florid hallucinations and delusions, reported increased distress on day 60, 
accompanied by a moderately elevated report of delusions.  However, over the 60-day treatment, 
he reported decreased hallucinatory behavior and relatively constant believability.  It is possible 
that as a function of declining hallucinatory symptoms, Participant 1 became more uncertain of 
his perceptions, which resulted in increased distress.  Participant 2, a 32-year old male diagnosed 
with impulse control disorder, reported consistently high distress during the 60-day treatment.  He 
reported increased delusional behavior as well as believability.  Though there is insufficient data 
to allow for proper analysis, one can speculate the functional nature of distress in these two cases 
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is correlated with age, chronicity, and perhaps believability.  This manifestation will be further 
analyzed once all 20 participants have completed the study. 
 This study represents a first step in testing psychosocial mechanisms of action in a 
biological treatment study.  Though conclusions cannot be drawn due to study limitations, future 
directions should still be explored.  And though these data will be re-analyzed within the larger 
treatment study once all 20 participants have completed treatment, further controlled research 
using larger samples will be necessary to determine whether believability is a mechanism of 
change beyond ACT and other psychotherapies.   
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APPENDIX A: Tables and Figures 
 
Table 1 
 
Raw score means (SDs) of pre- mid- and post (days 1, 30, 60) measures for completers; FBDH 
mean scores (SDs) are compiled Z-scores 
   
Measures Completers n = 6   
 
Active Drug n=4 Placebo n = 2 
PSYRATS_H_ TOT     
Day 1 12.75 (14.997) 0.00 
Day 30 12 .00 (10.954) 0.00 
Day 60 6.25 (12.500) 0.00 
PSYRATS_D_TOT 
  Day 1 8.25 (6.021) 2.5 (3.536) 
Day 30 5.75 (7.228) 3.5 (4.950) 
Day 60 9.50 (7.326) 4.00 (5.657) 
PSYRATS_H_sub scales 
  Day 1 2 / 0.5 (2.309 / 0.577) 0.00 
Day 30 1.75 / 0.5 (1.258 / 0.577) 0.00 
Day 60 0.75 / 0.25 (1.5 / 0.5) 0.00 
PSYRATS_D_sub scales 
  Day 1 2.25 / 1 (1.706 / 0.816) 0.5 / 0.5 (0.707 / 0.707) 
Day 30 1.5 / 0.5 (1.915 / 0.577)  1 / 0.5 (1.414 / 0.707) 
Day 60 2.25 / 1 (1.708 / 0.816) 1 / 0.5 (1.414 / 0.707) 
PANSS_H_sub scale 
  Day 1 3 (2.449) 3 (2.828) 
Day 30 3 (1.633) 0.5 (0.707) 
Day 60 2.75 (1.708) 2.5 (2.121) 
PANSS_D_sub scale 
  Day 1 3.25 (2.872) 1.5 (0.707) 
Day 30 3 (2.16) 0.5 (0.707) 
Day 60 3.25 (2.217) 2 (1.414) 
FBDH_F 
  Day 1 1.052 (0.476) 0.84 (0.099) 
Day 30 0.735 (0.4334) 0.77 (0.00) 
Day 60 0.9125 (0.598) 0.63 (0.197) 
FBDH_B 
  Day 1 1.002 (0.327) 0.71 (0.226) 
Day 30 0.69 (0.499) 0.87 (0.00) 
Day 60 1.005 (0.332) 0.825 (0.064) 
FBDH_D 
  Day 1 0.793 (0.184) 1.135 (0.502) 
Day 30 0.566 (0.306) 0.78 (0.00) 
Day 60 1.023 (0.968) 1.135 (0.502) 
   
PSYRATS_H/D_TOT: Psychotic Symptoms Ratings audio (h)allucinations/ (d)elusions totals; 
PSYRATS_H_sub scales: belief re-origin of voices / Amount of distress; PSYRATS_D_sub scales: current 
conviction (at time of interview) / amount of distress; PANSS_H/D: Positive and Negative Syndrome Scale 
(h)allucinatory behavior and (d)elusions); FBDH: (F)requency, (B)elievability, and (D)istress of 
Hallucinations [FBDH scores were converted into z-scores] 
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Table 2  
 
Individual Raw scores for all participants on Psychotic Rating Scales (PSYRATS) auditory 
hallucinations and delusions scales 
 
  
Day 1 
AH 
Day 30 
AH 
Day 60 
AH 
Day 1 
D 
Day 30 
D  
Day 60  
D 
Participant 1 (ag) 29 26 25 14 15 17 
Participant 2 (p) 0 0 0 0 7 8 
Participant 3 (ag) 0 0 0 0 0 0 
Participant 4 (ag) 0 8 0 8 0 8 
Participant 5 (p) 0 0 0 5 0 0 
Participant 6 (ag) 22 14 0 11 8 13 
 
AH= Auditory hallucinations; D= Delusions 
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Table 3 
 
Individual Z scores for all participants on the Frequency, Believability, and Distress of 
Hallucinations (FBDH) scale 
 
  
Day 1 
F 
Day 30 
F 
Day 60 
F 
Day 1 
B 
Day 30 
B 
Day 60 
B 
Day 1 
D 
Day 30 
D 
Day 60 
D 
Participant 1 (ag) .96 .91 .96 .96 .90 .93 .85 .72 .99 
Participant 2 (p) .82 .22 .69 .71 .19 .79 .93 .22 .93 
Participant 3 (ag) .22 .22 .22 .19 .19 .19 .22 .22 .22 
Participant 4 (ag) .22 .69 .22 .19 .53 .19 .22 .22 .22 
Participant 5 (p) .22 .22 .22 .19 .19 .19 .22 .22 .22 
Participant 6 (ag) .82 .36 .36 .79 .71 .79 .72 .55 .55 
 
F= Frequency; B= Believability; D= Distress 
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Table 4 
 
Demographic Data 
 
 Percentage 
(n=6) 
Gender 
     Male 
     Female 
 
83% (5) 
17% (1) 
Ethnicity 
     White 
     African American 
     Other 
 
100% (6) 
Diagnosis 
     Schizophrenia 
     Schizoaffective 
     Other 
 
33% (2) 
17% (1) 
50% (3) 
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Figure 1.  Proposed model of mediation examining whether positive symptom believability 
mediates the relationship between treatment condition and positive symptom related distress 
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Individual Graphs 
 
 
 
 
Figure 2: Participant 1 (Active Drug) 
 
 
 
 
 
Figure 3: Participant 1 (Active Drug) 
 
 
 47 
 
 
Figure 4: Participant 1 (Active Drug) 
 
 
 
 
 
Figure 5: Participant 1 (Active Drug) 
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Figure 6: Participant 1 (Active Drug) 
 
 
 
 
 
Figure 7: Participant 1 (Active Drug) 
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Figure 8: Participant 2 (Placebo) 
 
 
  
 
 
Figure 9: Participant 2 (Placebo) 
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Figure 11: Participant 2 (Placebo) 
 
 
 
 
 
Figure 12: Participant 2 (Placebo) 
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Figure 13: Participant 2 (Placebo) 
 
 
 
 
 
Figure 14: Participant 2 (Placebo) 
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Figure 15: Participant 3 (Active Drug) 
 
 
 
 
 
Figure 16: Participant 3 (Active Drug) 
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Figure 17: Participant 3 (Active Drug) 
 
 
 
  
 
Figure 18: Participant 3 (Active Drug) 
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Figure 19: Participant 3 (Active Drug) 
 
 
 
 
 
Figure 20: Participant 3 (Active Drug) 
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Figure 21: Participant 4 (Active Drug) 
 
 
 
 
 
Figure 22: Participant 4 (Active Drug) 
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Figure 23: Participant 4 (Active Drug) 
 
 
 
 
 
Figure 24: Participant 4 (Active Drug) 
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Figure 25: Participant 4 (Active Drug) 
 
 
 
 
 
Figure 26: Participant 4 (Active Drug) 
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 Figure 27: Participant 5 (Placebo) 
 
 
 
 
 
Figure 28: Participant 5 (Placebo) 
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Figure 29: Participant 5 (Placebo)  
 
 
 
 
 
Figure 30: Participant 5 (Placebo) 
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Figure 31: Participant 5 (Placebo) 
 
 
 
 
 
Figure 32: Participant 5 (Placebo) 
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Figure 33: Participant 6 (Active Drug) 
 
 
   
 
 
Figure 34: Participant 6 (Active Drug) 
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Figure 35: Participant 6 (Active Drug) 
 
 
 
 
 
Figure 36: Participant 6 (Active Drug) 
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Figure 37: Participant 6 (Active Drug) 
 
 
 
 
 
Figure 38: Participant 6 (Active Drug) 
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Group Graphs (Active Drug vs. Placebo) 
 
 
 
 
Figure 39: PSYRATS Total Auditory Hallucinations 
 
 
 
 
 
Figure 40: PSYRATS Total Delusions 
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Figure 41: PANSS Positive Scale Total Scores 
 
 
 
 
 
Figure 42: PANSS Hallucinatory Behavior Item 
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Figure 43: PANSS Delusion Item 
 
 
 
 
 
Figure 44: FBDH Frequency of Hallucinations 
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Figure 45: FBDH Believability of Hallucinations 
 
 
 
 
 
Figure 46: FBDH Distress Associated with Hallucinations 
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APPENDIX B: Measures 
 
AUDITORY HALLUCINATION RATING SCALE 
(Haddock et al 1999) 
 
The following structured interview is designed to elicit specific details regarding different 
dimensions of auditory hallucinations.   
 
Record answers below based on the patient’s experiences over the last week.  However, 
when rating conviction, ask the patient about their conviction at the time of the interview. 
 
 
1. Frequency of Voices 
 
How often do you hear voices?   
 
0 Voices not present or present less than once a week 
1 Voices occur for at least once a week 
2 Voices occur at least once a day 
3 Voices occur at least once an hour 
4 Voices occur continuously or almost continuously (i.e., stop for only a few seconds or 
minutes) 
 
2. Duration of Voices 
 
When you hear voices, how long do they persist?   
 
0 Voices not present 
1 Voices last for a few seconds, fleeting voices 
2 Voices last several minutes 
3 Voices last for at least one hour 
4 Voices last for hours at a time 
 
3. Location of Voices 
 
Where does it sound like the voices are located e.g. inside head, outside head, or both? 
 
0 No voices present 
1 Voices sound like they are inside head only  
2 Voices outside the head, but close to ears or head.  Voices inside the head may also 
be present 
3 Voices sound like they are inside or close to ears and outside head away from ears 
4 Voices sound like they are from outside the head only 
 
4. Loudness of Voices 
 
How loud are the voices?   
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0 Voices not present 
1 Quieter than own voice, whispers. 
2 About same loudness as own voice 
3 Louder than own voice 
4 Extremely loud, shouting 
 
5. Beliefs Re-Origin of Voices 
 
From where do you believe the voices originate e.g. internally within one’s self or 
externally? 
 
0 Voices not present 
1 Believes voices to be solely internally generated and related to self 
2 Holds <50% conviction that voices originate from external causes 
3 Holds !50% conviction (but < 100%) that voices originate from external causes 
4 Believes voices are solely due to external causes (100 % conviction)   
 
6. Amount of Negative Content of Voices 
 
Do the voices say negative or unpleasant things?  How much of the time? 
 
0 No unpleasant content 
1 Occasional unpleasant content (<10%) 
2 Minority of voice content is unpleasant or negative (<50%) 
3 Majority of voice content is unpleasant or negative (!50%) 
 
7. Degree of Negative Content 
 
What do the negative or unpleasant voices say?   
 
0 Not unpleasant or negative 
1 Some degree of negative content, but not personal comments relating to self or family 
e.g. swear words or comments not directed to self, e.g. ‘the milkman’s ugly’ 
2 Personal verbal abuse, comments on behavior e.g. ‘shouldn’t do that or say that’ 
3 Personal verbal abuse relating to self-concept e.g. ‘you’re lazy, ugly, mad, perverted’ 
4 Personal threats to self e.g. threats to harm self or family, extreme instructions or 
commands to harm self or others 
8. Amount of Distress 
 
Do the voices cause you distress?  How much of the time do they cause you distress? 
 
0 Voices not distressing at all 
1 Voices occasionally distressing, majority not distressing (<10%) 
2 Minority of voices distressing (<50%) 
3 Majority of voices distressing, minority not distressing (!50%) 
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4 Voices always distressing 
9. Intensity of Distress 
 
When the voices distress you, how severe does this feel? 
 
0 Voices not distressing at all 
1 Voices slightly distressing 
2 Voices are distressing to a moderate degree 
3 Voices are very distressing, although subject could feel worse 
4 Voices are extremely distressing, feel the worst he/she could possibly feel 
 
10. Disruption to Life Caused by Voices 
 
How much disruption do the voices cause you?  Do you think the voice(s) is related to 
your hospitalization?  Do they prevent you from working or carrying out daytime 
activity?  Do they interfere with your relationships with family and friends?  Do they 
interfere with your ability to look after yourself e.g. washing, changing clothes? 
 
0 No disruption to life, able to maintain social and family relationships (if present) 
1 Voices causes minimal amount of disruption to life e.g. interferes with concentration 
although able to maintain daytime activity and social and family relationships and be 
able to maintain independent living without support 
2 Voices cause moderate amount of disruption to life causing some disturbance to 
daytime activity and/or family or social activities.  The patient is not in hospital 
although may live in supported accommodation or receive additional help with daily 
living skills 
3 Voices cause severe disruption to life so that hospitalization is usually necessary.  The 
patient is able to maintain some daily activities, self-care and relationships while in 
hospital.  The patient may also be in supported accommodation but experiencing 
severe disruption of life in terms of activities, daily living skills and/or relationships. 
4 Voices cause complete disruption of daily life requiring hospitalization.  The patient 
is unable to maintain any daily activities and social relationships.  Self-care is also 
severely disrupted. 
 
11. Controllability of Voices 
 
Do you feel like you can have control over the voices?  How much of the time? 
 
0  Subject believes they can have control over the voices and can always bring on or 
dismiss them at will 
1 Subject believes they can have some control over the voices on the majority of 
occasions 
2 Subject believes they can have some control over the voices approximately half the 
time 
3 Subject believes they can have some control over their voices but only occasionally.  
They majority of the time the subject experiences voices which are uncontrollable 
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4 Subject has no control over when the voices occur and cannot dismiss or bring them 
on at all 
 
 
 
 
AUDITORY HALLUCINATION RATING SCALE 
SCORE SHEET  
 
 
1.    Frequency of Voices    _____ 
 
2.    Duration of Voices    _____ 
 
3.    Location of Voices    _____ 
 
4.    Loudness of Voices    _____ 
 
5.    Beliefs Re-Origin of Voices   _____ 
 
6.    Amount of Negative Content   _____ 
 
7.    Degree of Negative Content   _____ 
 
8.    Amount of Distress    _____ 
 
9.    Intensity of Distress    _____ 
 
                 10.   Disruption to Life          _____ 
  
      11.   Controllability of Voices         _____ 
 
Total Score:   _____ 
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DELUSION RATING SCALE 
(Haddock et al 1999) 
 
The following structured interview is designed to elicit specific details regarding different 
dimensions of delusional beliefs.  When asking questions the interview is designed to rate 
the patients experiences over the last week for the majority of the items.  There is one 
exception to this, when rating conviction, ask the patient about their conviction at the 
time of the interview.  
*Note: If previous delusions are not currently present, check here: _____ and only 
complete question 3. 
 
1. AMOUNT OF PREOCCUPATION WITH DELUSIONS 
How much time do you spend thinking of your beliefs?   
-all the time/daily/weekly etc. 
 
0   No delusions or delusions which the patient thinks about less than once a week. 
 (specify frequency if present) 
1  Patient thinks about beliefs at least once a week. 
2    Subject thinks about beliefs once a day. 
3    Subject thinks about beliefs once an hour. 
4    Subject thinks about delusions continuously or almost continuously. Subject can only 
think about other  
      things for few seconds or minutes. 
 
2. DURATION OF PREOCCUPATION WITH DELUSIONS 
When the beliefs come into your mind, how long do they persist? 
-few seconds/minutes/hours etc. 
 
0    No delusions. 
1    Thoughts about beliefs last for a few seconds, fleeting thoughts. 
2    Thoughts about delusions last for several minutes. 
3    Thoughts about delusions last for at least an hour. 
4    Thoughts about delusions usually last for hours at a time. 
 
3. CONVICTION (at the time of interview) 
At the present time how convinced are you that your beliefs are true?  Even if these 
thoughts or concerns were not bothering you this week, how convinced are you today that 
they WERE true when you had them before (specify time period if necessary)?  Can you 
estimate this on a scale from 0-10, where 10 means that you are totally convinced by your 
beliefs and 0 being that you are not convinced at all. 
 
0    No conviction at all. 
1    Very little conviction in reality of beliefs, less than 10% 
2    Some doubts relating to conviction in beliefs, between 10-49% 
3    Conviction in belief is very strong, between 50-99% 
4    Conviction is 100% 
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4. AMOUNT OF DISTRESS 
Do your beliefs cause you distress?  How much of the time do they cause you distress?  
 
0    Beliefs never cause distress 
1    Beliefs cause distress on the minority of occasions 
2    Beliefs cause distress on approximately 50% of occasions 
3    Beliefs cause distress on the majority of occasions when they occur between 
      50-99% of the time 
4    Beliefs always cause distress when they occur. 
 
 
5. INTENSITY OF DISTRESS 
When your beliefs distress you, how severe does this feel?   
 
0    No distress 
1    Beliefs cause slight distress 
2    Beliefs cause moderate distress 
3    Beliefs cause marked distress 
4    Beliefs cause extreme distress, couldn't be worse 
 
 
6. DISRUPTION TO LIFE CAUSED BY BELIEFS 
How much disruption do your beliefs cause you?  Do you think your belief(s) is related to 
your hospitalization? 
- do they prevent you from working or carrying out daytime activity ? 
- do they interfere with your relationships with family or friends ? 
- do they interfere with your ability to look after yourself e.g. washing, 
  changing clothes. 
 
0    No disruption to life, able to maintain independent living with no problems in daily 
living   
      skills. Able to maintain social and family relationships (if present) 
1    Beliefs cause minimal amount of disruption to life e.g. interferes with concentration,    
      although able to maintain daytime activity and social and family relationships and be 
able to  
      maintain independent living without support. 
2    Beliefs cause moderate amount of disruption to life causing some disturbance to 
daytime   
      activity and/or social activities. The patient is not in hospital although may live in 
supported  
      accommodation or receive additional help with daily living skills. 
3    Beliefs cause severe disruption to life so that hospitalization is usually necessary.  
The   
      patient is able to maintain some daily activities, self-care and relationships whilst in 
hospital.    
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      The  patient may also be in supported accommodation but experiencing severe 
disruption of   
      life in terms of activities, daily living skills and/or relationships. 
4    Beliefs cause complete disruption of daily life requiring hospitalization. The patient is 
unable  
      to maintain any daily activities and social relationships. Self care is also severely 
disrupted. 
 
 
GENERAL QUESTIONS 
Length of time of delusional beliefs (years) ? ............ 
Please specify individual delusional beliefs: 
............................................................................................................................................... 
................................................................................................................................................ 
................................................................................................................................................ 
 
 
DELUSION RATING SCALE 
SCORE SHEET 
 
 
1.    Amount of Preoccupation     _____ 
 
2.    Duration of Preoccupation     _____ 
 
3.    Current Conviction               _____ 
 
4.    Amount of Distress               _____ 
 
5.   Intensity of Distress                          _____ 
 
6.    Disruption to Life                           _____ 
 
 
           Total Score:   _____ 
 
 
 
 
 
 
 
 
 
 
 75 
FREQUENCY, BELIEVABILITY, AND DISTRESS  
OF HALLUCINATIONS RATING SCALE  
(Bach and Hayes, 2002) 
 
This assessment is to be used after completion of the PANSS.  Use information provided 
on the PANSS (e.g. specific hallucination) for questions below. 
 
1. FREQUENCY OF HALLUCINATIONS  
On average, how often have you experienced [specific hallucination]? 
 
1----------2----------3----------4----------5----------6----------7 
 
1 Never 
2 Less than once a week 
3 About once a week 
4 Several times a week 
5 Daily 
6 More than once a day 
7 Almost constantly 
 
2.  BELIEVABILITY OF HALLUCINATIONS 
On a scale from 0-10, how much do you believe that [specific hallucination] is real or 
true? 
 
0-Zero means that you are certain it is not real or true 
10-means you are absolutely certain that it is real or true 
 
0---------1----------2----------3----------4----------5----------6----------7----------8----------9----
------10 
 
 
3.  DISTRESS ASSOCIATED WITH HALLUCINATIONS 
On a scale from 0-10, how bothered are you by [specific hallucination]? 
 
0-Zero means not distressed at all 
10- means you are the most distressed you’ve ever been 
 
0---------1----------2----------3----------4----------5----------6----------7----------8----------9----
------10 
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